Procept BioRobotics (PRCT) announced the commencement of an underwritten public offering of $175M of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26.25M of shares of the company’s common stock. Procept BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. BofA Securities, Piper Sandler and Morgan Stanley are acting as joint book-running managers for the proposed offering.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz
- Morning Movers: Philips plummets following third quarter results
- Procept BioRobotics reports Q3 EPS (40c), consensus (49c)
- Procept BioRobotics raises FY24 revenue view to $222.5M-$223M from $217M
- Is PRCT a Buy, Before Earnings?